297 related articles for article (PubMed ID: 26218634)
21. Actionable mutations in muscle-invasive bladder cancer.
Bambury RM; Rosenberg JE
Curr Opin Urol; 2013 Sep; 23(5):472-8. PubMed ID: 23907505
[TBL] [Abstract][Full Text] [Related]
22. Bladder cancer genomics.
Siracusano S; Rizzetto R; Porcaro AB
Urologia; 2020 May; 87(2):49-56. PubMed ID: 31942831
[TBL] [Abstract][Full Text] [Related]
23. Biological determinants of bladder cancer gene expression subtypes.
Aine M; Eriksson P; Liedberg F; Sjödahl G; Höglund M
Sci Rep; 2015 Jun; 5():10957. PubMed ID: 26051783
[TBL] [Abstract][Full Text] [Related]
24. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology.
Damrauer JS; Hoadley KA; Chism DD; Fan C; Tiganelli CJ; Wobker SE; Yeh JJ; Milowsky MI; Iyer G; Parker JS; Kim WY
Proc Natl Acad Sci U S A; 2014 Feb; 111(8):3110-5. PubMed ID: 24520177
[TBL] [Abstract][Full Text] [Related]
25. Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities.
Trilla-Fuertes L; Gámez-Pozo A; Prado-Vázquez G; Zapater-Moros A; Díaz-Almirón M; Arevalillo JM; Ferrer-Gómez M; Navarro H; Maín P; Espinosa E; Pinto Á; Vara JÁF
BMC Cancer; 2019 Jun; 19(1):636. PubMed ID: 31253132
[TBL] [Abstract][Full Text] [Related]
26. Intrinsic Molecular Subclassification of Urothelial Carcinoma of the Bladder: Are We Finally there?
Akhtar M; Al-Bozom IA; Ben Gashir M; Taha NM
Adv Anat Pathol; 2019 Jul; 26(4):251-256. PubMed ID: 31188799
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
Jones RT; Felsenstein KM; Theodorescu D
Urol Clin North Am; 2016 Feb; 43(1):77-86. PubMed ID: 26614030
[TBL] [Abstract][Full Text] [Related]
28. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.
Sanchez-Carbayo M; Socci ND; Lozano J; Saint F; Cordon-Cardo C
J Clin Oncol; 2006 Feb; 24(5):778-89. PubMed ID: 16432078
[TBL] [Abstract][Full Text] [Related]
29. Bladder cancer stage and outcome by array-based comparative genomic hybridization.
Blaveri E; Brewer JL; Roydasgupta R; Fridlyand J; DeVries S; Koppie T; Pejavar S; Mehta K; Carroll P; Simko JP; Waldman FM
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7012-22. PubMed ID: 16203795
[TBL] [Abstract][Full Text] [Related]
30. Novel biomarkers in bladder cancer.
Cheng ML; Iyer G
Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
[TBL] [Abstract][Full Text] [Related]
31. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.
Wild PJ; Herr A; Wissmann C; Stoehr R; Rosenthal A; Zaak D; Simon R; Knuechel R; Pilarsky C; Hartmann A
Clin Cancer Res; 2005 Jun; 11(12):4415-29. PubMed ID: 15958626
[TBL] [Abstract][Full Text] [Related]
32. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
Lei Z; Tan IB; Das K; Deng N; Zouridis H; Pattison S; Chua C; Feng Z; Guan YK; Ooi CH; Ivanova T; Zhang S; Lee M; Wu J; Ngo A; Manesh S; Tan E; Teh BT; So JB; Goh LK; Boussioutas A; Lim TK; Flotow H; Tan P; Rozen SG
Gastroenterology; 2013 Sep; 145(3):554-65. PubMed ID: 23684942
[TBL] [Abstract][Full Text] [Related]
33. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.
Pignot G; Cizeron-Clairac G; Vacher S; Susini A; Tozlu S; Vieillefond A; Zerbib M; Lidereau R; Debre B; Amsellem-Ouazana D; Bieche I
Int J Cancer; 2013 Jun; 132(11):2479-91. PubMed ID: 23169479
[TBL] [Abstract][Full Text] [Related]
34. Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer.
Iyyanki T; Zhang B; Wang Q; Hou Y; Jin Q; Xu J; Yang H; Liu T; Wang X; Song F; Luan Y; Yamashita H; Chien R; Lyu H; Zhang L; Wang L; Warrick J; Raman JD; Meeks JJ; DeGraff DJ; Yue F
Genome Biol; 2021 Apr; 22(1):105. PubMed ID: 33858483
[TBL] [Abstract][Full Text] [Related]
35. SIU-ICUD consultation on bladder cancer: basic science.
McConkey DJ; Lerner SP
World J Urol; 2019 Jan; 37(1):15-29. PubMed ID: 30547196
[TBL] [Abstract][Full Text] [Related]
36. Screening biomarkers of bladder cancer using combined miRNA and mRNA microarray analysis.
Jin N; Jin X; Gu X; Na W; Zhang M; Zhao R
Mol Med Rep; 2015 Aug; 12(2):3170-6. PubMed ID: 25955758
[TBL] [Abstract][Full Text] [Related]
37. A place for precision medicine in bladder cancer: targeting the FGFRs.
di Martino E; Tomlinson DC; Williams SV; Knowles MA
Future Oncol; 2016 Oct; 12(19):2243-63. PubMed ID: 27381494
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer.
van der Vos KE; Vis DJ; Nevedomskaya E; Kim Y; Choi W; McConkey D; Wessels LFA; van Rhijn BWG; Zwart W; van der Heijden MS
Sci Rep; 2020 Jul; 10(1):10952. PubMed ID: 32616859
[TBL] [Abstract][Full Text] [Related]
39. Personalising the treatment of prostate cancer.
Gunjur A
Lancet Oncol; 2015 Dec; 16(16):e592. PubMed ID: 26549591
[No Abstract] [Full Text] [Related]
40. Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.
Hedegaard J; Lamy P; Nordentoft I; Algaba F; Høyer S; Ulhøi BP; Vang S; Reinert T; Hermann GG; Mogensen K; Thomsen MBH; Nielsen MM; Marquez M; Segersten U; Aine M; Höglund M; Birkenkamp-Demtröder K; Fristrup N; Borre M; Hartmann A; Stöhr R; Wach S; Keck B; Seitz AK; Nawroth R; Maurer T; Tulic C; Simic T; Junker K; Horstmann M; Harving N; Petersen AC; Calle ML; Steyerberg EW; Beukers W; van Kessel KEM; Jensen JB; Pedersen JS; Malmström PU; Malats N; Real FX; Zwarthoff EC; Ørntoft TF; Dyrskjøt L
Cancer Cell; 2016 Jul; 30(1):27-42. PubMed ID: 27321955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
